PDF(Pubmed)
Abstract：
UNASSIGNED: Dapsone forms the backbone of multi-drug therapy (MDT) in leprosy and many other dermatological disorders. Haemolysis is its common side effect which often necessitates drug stoppage. Currently, wide variation in data of haemolysis with dapsone exists in literature ranging from 24.7% to 83% and none of the studies point towards the timing of onset of haemolysis/timing of maximal haemolysis which is important in therapeutic decision making regarding continuing or stopping the drug. This study aimed to answer such unanswered questions.
UNASSIGNED: Primary: To estimate the fall in haemoglobin (Hb) levels after administering MDT for 3 months in patients with leprosy. Secondary: To determine factors associated with Hb change - age, glucose-6-phosphate dehydrogenase (G6PD) status, pole of leprosy and duration of MDT taken (if any).
UNASSIGNED: All freshly diagnosed cases of Hansen\'s disease were studied for 3 months. At baseline, demographic data (age, sex), skin biopsy, slit skin smear and G6PD were taken. Haemoglobin (Hb), serum glutamate oxaloacetate transferase (SGOT), serum glutamate pyruvate transferase (SGPT), serum bilirubin, lactate dehydrogenase (LDH), reticulocyte count, peripheral blood smear (PBS) along with clinical photography was done at baseline, 1, 2 and 3 months.
UNASSIGNED: Out of the 48 patients who completed the study: Mean Hb (g/dL) decreased from 13.37 at baseline to a minimum of 12.08 at 2 months, and then increased to 12.34 at 3 months. Of 42 patients (87.5%) with a fall in Hb, 13 (27.1%) had severe (fall >20%), 17 (35.4%) had moderate (fall 10-20%), 12 (25%) had mild fall (fall <10%) and in 6 (12.5%), there was no haemolysis. Reticulocyte count, LDH, SGOT and SGPT were significantly associated with haemolysis. Severe haemolysis occurred more frequently in the lepromatous spectrum.
UNASSIGNED: Dapsone causes maximal fall of hemoglobin by 1.29 g/dl at two months following which it increases. The fall of hemoglobin is reversible and hemoglobin starts to increase by 3 months of therapy making cessation of the drug unnecessary in most of the patients.
UNASSIGNED: Primary: To estimate the fall in haemoglobin (Hb) levels after administering MDT for 3 months in patients with leprosy. Secondary: To determine factors associated with Hb change - age, glucose-6-phosphate dehydrogenase (G6PD) status, pole of leprosy and duration of MDT taken (if any).
UNASSIGNED: All freshly diagnosed cases of Hansen\'s disease were studied for 3 months. At baseline, demographic data (age, sex), skin biopsy, slit skin smear and G6PD were taken. Haemoglobin (Hb), serum glutamate oxaloacetate transferase (SGOT), serum glutamate pyruvate transferase (SGPT), serum bilirubin, lactate dehydrogenase (LDH), reticulocyte count, peripheral blood smear (PBS) along with clinical photography was done at baseline, 1, 2 and 3 months.
UNASSIGNED: Out of the 48 patients who completed the study: Mean Hb (g/dL) decreased from 13.37 at baseline to a minimum of 12.08 at 2 months, and then increased to 12.34 at 3 months. Of 42 patients (87.5%) with a fall in Hb, 13 (27.1%) had severe (fall >20%), 17 (35.4%) had moderate (fall 10-20%), 12 (25%) had mild fall (fall <10%) and in 6 (12.5%), there was no haemolysis. Reticulocyte count, LDH, SGOT and SGPT were significantly associated with haemolysis. Severe haemolysis occurred more frequently in the lepromatous spectrum.
UNASSIGNED: Dapsone causes maximal fall of hemoglobin by 1.29 g/dl at two months following which it increases. The fall of hemoglobin is reversible and hemoglobin starts to increase by 3 months of therapy making cessation of the drug unnecessary in most of the patients.
摘要：
■氨苯砜是麻风病和许多其他皮肤病的多种药物治疗（MDT）的支柱。溶血是其常见的副作用，通常需要停药。目前,在文献中,氨苯砜溶血的数据差异很大,从24.7%到83%不等,没有一项研究指出溶血发生的时间/最大溶血的时间,这在继续或停止药物的治疗决策中很重要.这项研究旨在回答这些悬而未决的问题。
■主要：评估麻风病患者给予MDT3个月后血红蛋白（Hb）水平的下降。次要：确定与血红蛋白变化相关的因素-年龄，葡萄糖-6-磷酸脱氢酶（G6PD）状态，麻风病的极点和MDT的持续时间（如果有）。
■对所有新诊断的汉森病病例进行了3个月的研究。在基线,人口统计数据(年龄，sex),皮肤活检,取狭缝皮肤涂片和G6PD。血红蛋白(Hb),血清谷氨酸草酰乙酸转移酶（SGOT），血清谷氨酸丙酮酸转移酶（SGPT），血清胆红素，乳酸脱氢酶（LDH），网织红细胞计数,基线时进行外周血涂片（PBS）和临床摄影，1、2和3个月。
■在完成研究的48名患者中：平均Hb（g/dL）从基线时的13.37下降到2个月时的最低12.08，然后在3个月时增加到12.34。42例(87.5%)Hb下降,13人（27.1%）严重（下降>20%），17（35.4%）中等（下降10-20%），12人(25%)轻度跌倒(跌倒<10%)，6人(12.5%)，没有溶血。网织红细胞计数,LDH,SGOT和SGPT与溶血显著相关。在麻风病谱中，严重的溶血更为频繁。
■氨苯砜导致血红蛋白在两个月后最大下降1.29g/dl。血红蛋白的下降是可逆的,并且血红蛋白在治疗3个月时开始增加,使得在大多数患者中不必停止药物。
■主要：评估麻风病患者给予MDT3个月后血红蛋白（Hb）水平的下降。次要：确定与血红蛋白变化相关的因素-年龄，葡萄糖-6-磷酸脱氢酶（G6PD）状态，麻风病的极点和MDT的持续时间（如果有）。
■对所有新诊断的汉森病病例进行了3个月的研究。在基线,人口统计数据(年龄，sex),皮肤活检,取狭缝皮肤涂片和G6PD。血红蛋白(Hb),血清谷氨酸草酰乙酸转移酶（SGOT），血清谷氨酸丙酮酸转移酶（SGPT），血清胆红素，乳酸脱氢酶（LDH），网织红细胞计数,基线时进行外周血涂片（PBS）和临床摄影，1、2和3个月。
■在完成研究的48名患者中：平均Hb（g/dL）从基线时的13.37下降到2个月时的最低12.08，然后在3个月时增加到12.34。42例(87.5%)Hb下降,13人（27.1%）严重（下降>20%），17（35.4%）中等（下降10-20%），12人(25%)轻度跌倒(跌倒<10%)，6人(12.5%)，没有溶血。网织红细胞计数,LDH,SGOT和SGPT与溶血显著相关。在麻风病谱中，严重的溶血更为频繁。
■氨苯砜导致血红蛋白在两个月后最大下降1.29g/dl。血红蛋白的下降是可逆的,并且血红蛋白在治疗3个月时开始增加,使得在大多数患者中不必停止药物。
